Table 5.
Case report and case series of HSCT in MG patients.
| Study [Reference] |
Bryant, A., et al., 2016 [71] |
Sossa Melo, C.L. et al., 2019 [72] | Inan, B., et al., 2022 [75] |
Håkansson, I. et al., 2016 [73] | Mitsumune, S. et al., 2018 [76] | Strober, J. et al., 2009 [74] |
|---|---|---|---|---|---|---|
| N cases (gender) | 7 (6F, 1M) | 1 (M) | 1 (F) | 1 (F) | 1 (M) | 1 (M) |
| Age, y | 24–55 | 56 | 26 | 64 | 54 | 17 |
| HSCT | autologous | autologous | autologous | autologous | autologous | allogenic |
| Mobilisation of HSCs | Cy + G-CSF | Cy + G-CSF | Cy + G-CSF | RTX + G-CSF | N.R. | N.R. |
| Conditioning | Cy + TBI + ATG (n = 2); busulfan-Cy + ATG (n = 4); etoposide, melphalan + TBI (n = 1) |
Cy + ATG | Cy + ATG | BEAM + ATG | N.R. | Busulfan + fludarabine + alemtuzumab |
| Outcome | remission | remission | partial response | partial response | remission | partial response |
| Follow-up, m | N.R. | 65 | 30 | 24 | N.R. | 40 |
Continuous variables are reported as median/mean (range), where applicable. Abbreviations: ATG, anti-thymocyte globulin; Cy, cyclophosphamide; F, female; G-CSF, granulocyte-colony stimulating factor; m, months; M, male; N.R., not reported; RTX, rituximab; TBI, total body irradiation; y, years.